DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery

Information source: International Clinical Research Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Disorder of Knee

Intervention: Oxycodone (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: International Clinical Research Institute

Official(s) and/or principal investigator(s):
Srinivas Nalamachu, MD, Principal Investigator, Affiliation: International Clinical Research Institute

Overall contact:
Srinivas Nalamachu, MD, Phone: 913-317-5300, Email: sri@icrikansas.com

Summary

This is a pilot trial using this product in patients for the management of pain after outpatient arthroscopic knee surgery. This is an open-label study and the two active ingredients are well known pharmacologic entities.

Clinical Details

Official title: Open-Label Parallel Group Flexible Dosing & Titration Study to Evaluate the Efficacy, Safety of Oxycodone/APAP Extended Release Formulation Xartemisxr® in the Management of Post-Operative Pain Following Outpatient Arthroscopic Knee Surgery

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change in pain Scores on the Numerical Rating Scale

Secondary outcome: Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Detailed description: The objective of this single center is to evaluate the safety and efficacy of Oxycodone Extended Release (MNK-795) in postoperative pain following common musculoskeletal surgical procedures. Knee surgery being the most common surgery performed in the US, the investigators chose the model. The investigators also want to look at the flexible-dosing and titration which is the common way pain managed by clinicians. This is an open-label study of MNK 795 to be described in the procedures section. Primary endpoint: • Change in pain from baseline (before taking the first dose of study medication) measured on NRS Secondary endpoints:

- Patient/Investigator Global assessment of treatment satisfaction

- Safety evaluation with adverse event monitoring

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Individuals aged 18-75 who underwent an orthopedic outpatient surgical procedure of their knee 2. Read and understand English and comprehend the procedures associated with participating in a clinical trial. 3. Signed an IRB approved consent form and HIPAA authorization 4. Patients with a pain intensity score of 4 or above on the 0-10 numerical rating scale (0 is no pain, 10 is the worst pain imaginable) Exclusion Criteria: 1. Participants in any other clinical trial in the last 30 days or currently enrolled in a clinical trial 2. Allergy to Oxycodone or Acetaminophen. 3. Uncontrolled pain or other pain conditions that may interfere with evaluation 4. Pregnant women 5. Women who are trying to become pregnant 6. Women who are breastfeeding 7. Patient who is deemed to be medically unstable by the principal investigator 8. History of Alcohol, opioid or substance abuse in the last 2 yrs 9. History of sleep apnea that requires CPAP 10. History of serious respiratory illness 11. History of Gastric bypass 12. Prior use of opiates at doses higher than 90mg Morphine equivalent dosing 13. Will limit the study medication to 4 tab at each dosing and to total dose of 8 tab for 24 hrs. Subjects needing doses higher than that, based on their current opioid dose, will not be enrolled or discontinued

Locations and Contacts

Srinivas Nalamachu, MD, Phone: 913-317-5300, Email: sri@icrikansas.com

International Clinical Research Institute, Overland Park, Kansas 66210, United States; Recruiting
Srinivas Nalamachu, Phone: 913-317-5300, Email: Sri@icrikansas.com
Christy Kuechler, Phone: 913-317-5300, Email: christy@icrikansas.com
Srinivas Nalamachu, MD, Principal Investigator
Donna H Ruck, APRN, Sub-Investigator
Aakash Shah, MD, Sub-Investigator
Kathryn McConnaughey, APRN, Sub-Investigator
Jessica Molstad, APRN, Sub-Investigator
Jennifer Parks, APRN, Sub-Investigator
Additional Information

Starting date: May 2014
Last updated: March 12, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017